Accolade’s IPO happened at the right time when the pandemic is flourishing with a promised second wave around the globe. Healthcare stocks have been soaring since mid-February which was the first debuting moment of COVID-19 in China. Its Quick spread is a good work of globalization that keeps everyone in the global village.
If biotech companies find a cure for COVID-19 their stocks and revenue sales will surge but for a short time; two months maximum. So, personal and collective healthcare services are going to have slow growth in revenue or even a sharp fall.
Accolade is not an exception in that situation. Its quite inexpensive stock may stop surging and perhaps downtrend could be knocking its doors of trade due to a sharp fall in demand for healthcare services.
Before the end of COVID-19 pandemic NASDAQ: ACCD might enjoy triumphal uptrend and healthcare interested investors could enjoy it temporarily.
CEO and Editor in Chief.
Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life